Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show

Ofatumumab Better at Easing Relapse Rates and Slowing MS Progression Than Aubagio, Phase 3 Data Show

Publication date: Sep 03, 2019

Monthly injections of ofatumumab led to more clinically meaningful reductions in relapse rates and delayed disability progression than did daily treatment with Aubagio (teriflunomide) tablets in people with relapsing forms of multiple sclerosis (MS), results from two Phase 3 trials showed. -Ofatumumab, if approved, could be a highly attractive treatment option for a broad [relapsing MS] patient population, including early MS,” John Tsai, Novartis’s head global drug development and chief medical officer, said in a press release. The trials also showed that, at six months of treatment, patients give ofatumumab had fewer brain areas affected by active inflammation and disease activity, as well as fewer new or enlarging brain lesions, lesser brain volume loss, and lower blood levels of neurofilament light chain – a proposed MS biomarker. Published results of the Phase 2 MIRROR study (NCT01457924) also showed a marked reduction in new brain lesions over 48 weeks of treatment with ofatumumab compared to placebo. -This data signifies a possible turning point for ofatumumab and provides support for our belief that it has the potential, if approved, to become the first subcutaneous B-cell therapy for relapsing MS that can be self-administered by patients at home,” Jan van de Winkel, PhD, Genmab’s CEO, said in a separate press release.

Concepts Keywords
ASCLEPIOS Cell therapy
B Cell MS
B Cells Chronic lymphocytic leukemia
Biomarker Active inflammation
Blood Cell therapy
Brain Chronic lymphocytic leukemia
CD20 Novartis
CEO CD20
Chronic Lymphocytic Leukemia RTT
Disability Genmab
Double Blind Multiple sclerosis
Inflammation Biotechnology
Infusion Ofatumumab
Metabolism Breakthrough therapy
Monoclonal Antibody Life sciences
Multiple Sclerosis Health
Neurofilament
Novartis
Pharmacokinetic
PhD
Placebo
Progressive
Relapse
Sanofi
Stockholm
Subcutaneous
Tablets
UCSF

Semantics

Type Source Name
drug DRUGBANK Ofatumumab
drug DRUGBANK Tropicamide
disease MESH Relapse
drug DRUGBANK Teriflunomide
disease MESH multiple sclerosis
disease DOID multiple sclerosis
gene UNIPROT MS4A1
disease DOID chronic lymphocytic leukemia
disease DOID blood cancer
gene UNIPROT ARID1A
disease MESH development
pathway BSID Release
drug DRUGBANK Antithymocyte immunoglobulin (rabbit)
gene UNIPROT AICDA
drug DRUGBANK Methionine
gene UNIPROT SLTM
gene UNIPROT MET
disease MESH inflammation
gene UNIPROT TNFSF14
pathway BSID Metabolism
gene UNIPROT TNIP1
gene UNIPROT PDC

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *